Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents.

Cancer treatment reports Pub Date : 1987-10-01
R S Gelman, D C Tormey, R Betensky, E G Mansour, H C Falkson, G Falkson, R H Creech, D G Haller
{"title":"Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents.","authors":"R S Gelman,&nbsp;D C Tormey,&nbsp;R Betensky,&nbsp;E G Mansour,&nbsp;H C Falkson,&nbsp;G Falkson,&nbsp;R H Creech,&nbsp;D G Haller","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This study of 2382 breast, 182 rectal, 817 colon, and 351 lung cancer patients treated with combination chemotherapy on eight phase III Eastern Cooperative Oncology Group protocols indicates that 69% would receive a higher dose of at least one drug if surface area were calculated from actual weight rather than from the minimum of actual and ideal weight. Forty-eight percent of the patients would have at least a 10% increase in drug dose based on actual weight. Only on the premenopausal adjuvant breast cancer protocol and among women on the rectal adjuvant study do the differences in dose based on actual rather than ideal weight increase significantly with age. On the postmenopausal adjuvant breast study and on the lung cancer study, the differences in dose decrease significantly with age. For all age decades and both sexes within each protocol, the mean differences between dose based on actual and dose based on ideal weights were on the same order as the rounding factors for the 11 drugs studied. From the literature on the effect of doses of common chemotherapies on leukopenia, it appears that the percent of hematologic toxicity would not be raised to unacceptable levels by using actual weight to set doses.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This study of 2382 breast, 182 rectal, 817 colon, and 351 lung cancer patients treated with combination chemotherapy on eight phase III Eastern Cooperative Oncology Group protocols indicates that 69% would receive a higher dose of at least one drug if surface area were calculated from actual weight rather than from the minimum of actual and ideal weight. Forty-eight percent of the patients would have at least a 10% increase in drug dose based on actual weight. Only on the premenopausal adjuvant breast cancer protocol and among women on the rectal adjuvant study do the differences in dose based on actual rather than ideal weight increase significantly with age. On the postmenopausal adjuvant breast study and on the lung cancer study, the differences in dose decrease significantly with age. For all age decades and both sexes within each protocol, the mean differences between dose based on actual and dose based on ideal weights were on the same order as the rounding factors for the 11 drugs studied. From the literature on the effect of doses of common chemotherapies on leukopenia, it appears that the percent of hematologic toxicity would not be raised to unacceptable levels by using actual weight to set doses.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
表面积计算中的实际重量与理想重量:对11种化疗药物剂量的影响。
本研究对2382例乳腺癌患者、182例直肠癌患者、817例结肠癌患者和351例肺癌患者进行了8个东方肿瘤合作组III期方案的联合化疗,结果表明,如果根据实际体重计算表面积,而不是根据实际体重和理想体重的最小值计算表面积,69%的患者会接受至少一种药物的更高剂量。48%的患者会根据实际体重至少增加10%的药物剂量。只有在绝经前乳腺癌辅助治疗方案和直肠辅助治疗研究的女性中,基于实际体重而不是理想体重的剂量差异随着年龄的增长而显著增加。在绝经后辅助乳腺癌研究和肺癌研究中,剂量差异随着年龄的增长而显著减小。在每个方案中,对于所有年龄和性别,基于实际重量的剂量和基于理想重量的剂量之间的平均差异与所研究的11种药物的舍入因子的顺序相同。从常用化疗剂量对白细胞减少的影响的文献来看,使用实际体重来设定剂量似乎不会将血液学毒性的百分比提高到不可接受的水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Identification of new drugs in small cell lung cancer: phase II agents first?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1